Linfoma no Hodgkin en adultos: Tratamiento (PDQ®) - National ...

Linfoma no Hodgkin en adultos: Tratamiento (PDQ®) - National Cancer Institute
13. Escalón MP, Champlin RE, Saliba RM, et al.: Nonmyeloablative allogeneic hematopoietic transplantation:
a promising salvage therapy for patients with non-Hodgkin's lymphoma whose disease has failed a prior
autologous transplantation. J Clin Oncol 22 (12): 2419-23, 2004. [PUBMED Abstract]
14. Freytes CO, Loberiza FR, Rizzo JD, et al.: Myeloablative allogeneic hematopoietic stem cell
transplantation in patients who experience relapse after autologous stem cell transplantation for lymphoma:
a report of the International Bone Marrow Transplant Registry. Blood 104 (12): 3797-803, 2004. [PUBMED
Abstract]
15. Rezvani AR, Norasetthada L, Gooley T, et al.: Non-myeloablative allogeneic haematopoietic cell
transplantation for relapsed diffuse large B-cell lymphoma: a multicentre experience. Br J Haematol 143
(3): 395-403, 2008. [PUBMED Abstract]
16. Larouche JF, Berger F, Chassagne-Clément C, et al.: Lymphoma recurrence 5 years or later following
diffuse large B-cell lymphoma: clinical characteristics and outcome. J Clin Oncol 28 (12): 2094-100, 2010.
[PUBMED Abstract]
17. Rodriguez MA, Cabanillas FC, Velasquez W, et al.: Results of a salvage treatment program for relapsing
lymphoma: MINE consolidated with ESHAP. J Clin Oncol 13 (7): 1734-41, 1995. [PUBMED Abstract]
18. Rizzieri DA, Sand GJ, McGaughey D, et al.: Low-dose weekly paclitaxel for recurrent or refractory
aggressive non-Hodgkin lymphoma. Cancer 100 (11): 2408-14, 2004. [PUBMED Abstract]
19. Kewalramani T, Zelenetz AD, Nimer SD, et al.: Rituximab and ICE as second-line therapy before
autologous stem cell transplantation for relapsed or primary refractory diffuse large B-cell lymphoma.
Blood 103 (10): 3684-8, 2004. [PUBMED Abstract]
20. Coiffier B, Haioun C, Ketterer N, et al.: Rituximab (anti-CD20 monoclonal antibody) for the treatment of
patients with relapsing or refractory aggressive lymphoma: a multicenter phase II study. Blood 92 (6):
1927-32, 1998. [PUBMED Abstract]
21. Tobinai K, Igarashi T, Itoh K, et al.: Japanese multicenter phase II and pharmacokinetic study of rituximab
in relapsed or refractory patients with aggressive B-cell lymphoma. Ann Oncol 15 (5): 821-30, 2004.
[PUBMED Abstract]
22. Fisher RI, Kaminski MS, Wahl RL, et al.: Tositumomab and iodine-131 tositumomab produces durable
complete remissions in a subset of heavily pretreated patients with low-grade and transformed non-
Hodgkin's lymphomas. J Clin Oncol 23 (30): 7565-73, 2005. [PUBMED Abstract]
23. Witzig TE, Gordon LI, Cabanillas F, et al.: Randomized controlled trial of yttrium-90-labeled ibritumomab
tiuxetan radioimmunotherapy versus rituximab immunotherapy for patients with relapsed or refractory lowgrade,
follicular, or transformed B-cell non-Hodgkin's lymphoma. J Clin Oncol 20 (10): 2453-63, 2002.
[PUBMED Abstract]
24. Wiseman GA, Gordon LI, Multani PS, et al.: Ibritumomab tiuxetan radioimmunotherapy for patients with
relapsed or refractory non-Hodgkin lymphoma and mild thrombocytopenia: a phase II multicenter trial.
Blood 99 (12): 4336-42, 2002. [PUBMED Abstract]
25. Dang NH, Hagemeister FB, Pro B, et al.: Phase II study of denileukin diftitox for relapsed/refractory B-
Cell non-Hodgkin's lymphoma. J Clin Oncol 22 (20): 4095-102, 2004. [PUBMED Abstract]
26. Yuen AR, Kamel OW, Halpern J, et al.: Long-term survival after histologic transformation of low-grade
follicular lymphoma. J Clin Oncol 13 (7): 1726-33, 1995. [PUBMED Abstract]
27. Bastion Y, Sebban C, Berger F, et al.: Incidence, predictive factors, and outcome of lymphoma
transformation in follicular lymphoma patients. J Clin Oncol 15 (4): 1587-94, 1997. [PUBMED Abstract]
28. Williams CD, Harrison CN, Lister TA, et al.: High-dose therapy and autologous stem-cell support for
chemosensitive transformed low-grade follicular non-Hodgkin's lymphoma: a case-matched study from the
European Bone Marrow Transplant Registry. J Clin Oncol 19 (3): 727-35, 2001. [PUBMED Abstract]
29. Tsimberidou AM, O'Brien S, Khouri I, et al.: Clinical outcomes and prognostic factors in patients with
Richter's syndrome treated with chemotherapy or chemoimmunotherapy with or without stem-cell
transplantation. J Clin Oncol 24 (15): 2343-51, 2006. [PUBMED Abstract]
30. Lee AY, Connors JM, Klimo P, et al.: Late relapse in patients with diffuse large-cell lymphoma treated
with MACOP-B. J Clin Oncol 15 (5): 1745-53, 1997. [PUBMED Abstract]
file:///Users/mauriciolema/Documents/MLMGuias_09_LinfomaNoHodgkin.webarchive
29/09/11 6:15
Página 52 de 61